Log in

NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

-0.70 (-11.95 %)
(As of 02/24/2020 07:34 AM ET)
Today's Range
Now: $5.16
50-Day Range
MA: $4.31
52-Week Range
Now: $5.16
Volume180,735 shs
Average Volume80,773 shs
Market Capitalization$52.12 million
P/E RatioN/A
Dividend YieldN/A
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ACER



Sales & Book Value

Annual SalesN/A
Book Value$4.64 per share


Net Income$-21,280,000.00


Market Cap$52.12 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc (NASDAQ:ACER) released its earnings results on Wednesday, November, 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.05. View Acer Therapeutics' Earnings History.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Acer Therapeutics.

What price target have analysts set for ACER?

5 brokers have issued 12-month target prices for Acer Therapeutics' stock. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' share price to reach $22.33 in the next twelve months. This suggests a possible upside of 332.8% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

What is the consensus analysts' recommendation for Acer Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

Has Acer Therapeutics been receiving favorable news coverage?

News coverage about ACER stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acer Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Acer Therapeutics.

Are investors shorting Acer Therapeutics?

Acer Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 442,900 shares, a drop of 8.8% from the December 31st total of 485,900 shares. Based on an average trading volume of 50,200 shares, the short-interest ratio is currently 8.8 days. Currently, 9.1% of the shares of the stock are short sold. View Acer Therapeutics' Current Options Chain.

Who are some of Acer Therapeutics' key competitors?

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Amarin (AMRN), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Anavex Life Sciences (AVXL) and Exelixis (EXEL).

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the folowing people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)
  • Mr. Harry S. Palmin, COO & CFO (Age 49)
  • Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)
  • Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)
  • Ms. Jeannie Kim, VP of Corp. Devel.

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.10%), Barclays PLC (0.97%), J. Goldman & Co LP (0.73%), Goldman Sachs Group Inc. (0.51%), Bank of Montreal Can (0.14%) and CWS Financial Advisors LLC (0.10%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View Institutional Ownership Trends for Acer Therapeutics.

Which institutional investors are selling Acer Therapeutics stock?

ACER stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Goldman Sachs Group Inc., State Street Corp and Bank of Montreal Can. View Insider Buying and Selling for Acer Therapeutics.

Which institutional investors are buying Acer Therapeutics stock?

ACER stock was acquired by a variety of institutional investors in the last quarter, including CWS Financial Advisors LLC, UBS Group AG and Barclays PLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $5.16.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $52.12 million. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is http://www.acertx.com/.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]

MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  480
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: FinTech

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel